Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.

Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.

Item
http://www.wikidata.org/entity/Q36885663
Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicinesCombination of Cl‑IB‑MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR‑dependent autophagy and mitotic catastrophe on human melanoma cells.Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursPharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Level of evidence for therapeutic drug monitoring of taxanes.N-acetylcysteine modulates the cytotoxic effects of Paclitaxel.The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats.
P2860

Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.

Item
http://www.wikidata.org/entity/Q36885663
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
@en
type
label
Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
@en
prefLabel
Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921